dianhydrogalactitol

Small moleculeexperimental

Clinical trial activity

5 trials · 8 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
4
Phase 3
0
Phase 4
0

Earliest trial started Oct 1, 2011 (NCT01478178)

Timeline

2010s

  1. Jan 1, 2011

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2017

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

  • DNACROSS-LINKING AGENT

    DNA cross-linking agent

Chemistry & pharmacology

Loading structure…

SMILES

O[C@H]([C@H](O)[C@@H]1CO1)[C@H]1CO1
Mol. weight
146.14 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • dianhydrogalactitol
  • dianhydrogalactitol
  • dianhydrogalactitol
  • nsc-1323313
  • nsc-1323313
  • val-083
  • val-083
  • val-083

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03281681Phase 1/Phase 2 (Phase 2)Jun 30, 2018Kintara Therapeutics, Inc., St. Joseph's Hospital and Medical Center - Phoenix, Arizona
NCT03050736Phase 2Jun 1, 2017Kintara Therapeutics, Inc., Sun Yat-Sen University
NCT03138629N/AMay 1, 2017Kintara Therapeutics, Inc.
NCT02717962Phase 2Jan 20, 2017Kintara Therapeutics, Inc., University of Texas at Houston
NCT01478178Phase 1/Phase 2 (Phase 2)Oct 1, 2011Florida Cancer Specialists, Sarasota, Kintara Therapeutics, Inc., Mayo Clinic, SCRI Development Innovations, University of California, San Francisco
Showing 5 of 5 trials
Page 1 / 1

Organizations

Research & Development (8)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Kintara Therapeutics, Inc.For profit5522011
Florida Cancer Specialists, SarasotaAcademic/Hospital1012011
Mayo ClinicAcademic/Hospital1012011
SCRI Development InnovationsFor profit1012011
St. Joseph's Hospital and Medical Center - Phoenix, ArizonaAcademic/Hospital1012018
Sun Yat-Sen UniversityAcademic/Hospital1012017
University of California, San FranciscoAcademic/Hospital1012011
University of Texas at HoustonAcademic/Hospital1012017
8 organizations
Page 1 / 1